Investor Presentaiton
3Q22 Business Results
Income Statement
Revenue Steady growth continued in RemsimaⓇ SC and all other products in Europe & the growth market led sound earnings, partially offset
sales reduction in North America
OP
: Achieved solid operating profit mainly driven by stable prescription & COGS improvement of the high-margin products such as
InflectraⓇ and RemsimaⓇ SC
NP
: Jumped by 238.9% YoY and 251.9% QoQ respectively as a result of the increase in non-operating profit due to weak Won
(KRW bn)
'21.3Q
'22.2Q
'22.3Q
% YoY
%QoQ
Revenue
409.1
519.0
496.4
21.3%
-4.4%
Gross Profit
74.7
140.9
153.1
105.0%
8.7%
(%)
18.3%
27.1%
30.8%
12.5%p
3.7%p
SG&A
52.7
66.8
80.6
52.9%
20.7%
(%)
12.9%
12.9%
16.2%
3.3%p
3.3%p
Personnel expenses
12.1
13.7
14.1
16.5%
2.9%
Research expenses
5.5
0.8
0.3
-94.5%
-62.5%
Advertising expenses
3.0
6.6
7.7
156.7%
16.7%
Commissions
14.9
24.3
33.1
122.1%
36.2%
Operating Profit
22.0
74.1
72.5
229.5%
-2.2%
(%)
5.4%
14.3%
14.6%
9.2%p
0.3%p
EBIT
52.5
95.2
185.2
252.8%
94.5%
Net Profit
40.6
39.1
137.6
238.9%
251.9%
Investor Relations 2022 4View entire presentation